Skip to main content Accessibility help

A Safety Assessment of Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Hemorrhagic, Hypovolemic Shock

  • Robert J. Przybelski (a1), Elaine K. Daily (a2), Jean Micheels (a3), Edward Sloan (a4), Pierre Mols (a5), Luc Corne (a6), Max D. Koenigsberg (a7), William H. Bickell (a8), Dan R. Thompson (a9), Jay D. Harviel (a10) and Stephen M. Cohn (a11)...



To determine the safety and possible efficacy of diaspirin cross-linked hemoglobin (DCLHb) in the treatment of patients in Class II–IV hemorrhagic, hypovolemic shock.


Multicenter, randomized, normal saline-controlled, dose-escalation study.


Eleven hospitals in the U.S. and Belgium.


One hundred and thirty-nine (139) hospitalized patients with Class II–IV hemorrhagic, hypovolemic shock within the previous 4 hours who still were requiring therapy for shock.


Beginning with the lowest dose, patients were randomized to receive 50,100, or 200 mL of either 10% DCLHb or normal saline infused intravenously over 15 minutes. Following infusion of either treatment, further fluid resuscitation could be given, as necessary, to maintain perfusion. Vital signs, laboratory assessments, blood and fluid administration, complications, and adverse events were recorded at various times from the end of infusion through 72 hours after infusion.


A total of 29 (13 DCLHb- and 16 saline-treated) patients died during the study period. Adverse events were experienced by 61% of patients in the DCLHb group and 53% of patients in the saline group; serious adverse events occurred in 28% of DCLHb-treated patients and 30% of saline-treated patients. The incidence of prospectively defined, clinical complications, including renal insufficiency and renal failure, was similar between the treatment groups except for the occurrence of dysrhythmias/conduction disorders, which occurred significantly more frequently in the saline-treated patients than the DCLHb-treated patients (p = 0.041). At the highest dose level (200 mL), statistically significant between-group differences were observed with greater increases in serum amylase, LDH, the isoenzymes LD1,2,4 and 5, and CK-MB in the DCLHb group compared to the control group; none were of clinical significance. The volume of blood administered did not differ between the groups. Overall 24- and 72-hour survival rates were similar between treatment groups, although the hospital discharge rate was slightly higher in the DCLHb-treated patients (80%) compared with the saline-treated patients (74%).


Administration of 50 to 200 mL of DCLHb to patients in hemorrhagic, hypovolemic shock was not associated with evidence of end organ toxuity or significant adverse events. Further studies involving larger doses and, perhaps, earlier administration of DCLHb are warranted.


Corresponding author

FCCM 5887 Woods Edge Road Madison, Wisconsin 53711 USA


Hide All
1. Dove, DB, Stahl, WM, DelGuercio, LRM: Five year review of deaths following urban trauma. J Trauma 1980;20(9):760766.
2. Falk, JL, O'Brien, JF, Kerr, R: Fluid resuscitation in traumatic hemorrhagic shock. Crit Care Clinks 1992;8(2):323340.
3. Bickell, WH, Wall, MJ Jr, Pepe, PE et al. : Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994;331:11051109.
4. Dodd, RY: The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419421.
5. Klein, HG: Allogeneic transfusion risks in the surgical patient. Am J Surg 1995;170(6A):21S26S.
6. Amberson, WR, Jennings, JJ, Rhode, CM: Clinical experience with hemoglobin saline solutions. J Appl Physiol 1949;1(7):469489.
7. Savitsky, JP, Doczi, J, Black, J, Arnold, JD: A clinical safety trial of stromafree hemoglobin. Clin Pharmacol Ther 1978;23:7380.
8. Feola, MJ, Simoni, J, Canizaro, PC, Traqn, R, Raschbaum, G, Behal, FJ: Toxicity of polymerized hemoglobin solutions. Surg Gynecol Obstet 1988;166:211222.
9. Przybelski, RJ, Malcolm, DS, Burris, DG, Winslow, RM: Cross-linked hemoglobin solution as a resuscitative fluid after hemorrhage in the rat. J Lab Clin Med 1991;117(2):143151.
10. Malcolm, D, Kissinger, D: Diaspirin cross-linked hemoglobin solution as a resuscitative fluid following severe hemorrhage in the rat. Biomat Art Cells Immobil Biotech 1992;20:495497.
11. Dunlap, E, Farrell, L, Marchand, G, Gillies, B, Estep, T, Burhop, K: New blood product: Diaspirin cross-linked hemoglobin as a blood substitute. Efficacy in a pig model of hemorrhagic shock. Transfusion 1992;32S–9S.
12. Malcolm, D, Andrus, J: Exchange-transfusion with diaspirin cross-linked hemoglobin in rats. Circ Shock 1992;37(1):19. Abstract.
13. Cohn, SM, Farrell, TJ: Diaspirin cross-linked hemoglobin resuscitation of hemorrhage: Comparison of a blood substitute with hypertonic saline and isotonic saline. J Trauma: Injury Infection Crit Care 1995;39(2): 210217.
14. Schultz, SC, Hamilton, IN, Malcolm, DS: Use of base deficit to compare resuscitation with lactated Ringer's solution, haemaccel, whole blood, and diaspirin cross-linked hemoglobin following hemorrhage in rats. J Trauma 1993;35(4):619626.
15. Powell, CC, Schultz, SC, Burris, DG, Drucker, WR, Malcolm, DS: Resuscitation with diaspirin cross-linked hemoglobin (DCLHb) restores subcutaneous oxygen tension as well as blood in rats. Surg Forum 1993;44:4042.
16. Frankel, HL, Nguyen, HB, Shea-Donohue, T, Alton, L, Ratigan, J, Malcolm, DS: Diaspirin cross-linked hemoglobin (DCLHb) is efficacious in gut resuscitation as measured by a GI tract optode. J Trauma 1996;40(2):231241.
17. Schultz, SC, Powell, CC, Burris, DG, Nguyen, H, Jaffin, J, Malcolm, DS: The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a model of uncontrolled hemorrhage. J Trauma 1994;3(73):408412.
18. McKenzie, JE, Scandling, DM, Rohrer, MJ, Jacot, JL: Diaspirin crosslinked hemoglobin (DCLHb): Improvement in regional blood flow following administration in hypovolemic shock in the swine. Vtb Int'l Symposium on Blood Substitutes 1993 Program and Abstracts.
19. Gulati, A, Sen, AP, Singh, R: Diaspirin crosslinked hemoglobin, a hemoglobin-based blood substitute, improves the survival and regional blood circulation in severely hemorrhaged rats. Artif Cells Blood Subs Immobil Biotech 1996;24(4):344. Abstract.
20. Zingarelli, B, Squadrito, F, Altavilla, D, Calapai, G, Campo, GM, Calo, M, Saitta, A, Caputi, AP: Evidence for a role of nitric oxide in hypovolemic hemorrhagic shock. J Cardiovasc Pharmacol 1992;19:982986.
21. Yao, Y-M, Bahrami, S, Leichtfried, G, Redl, H, Schlag, G: Significance of NO in hemorrhage-induced hemodynamic alterations, organ injury, and mortality in rats. Am J Physiol 1996;270:H16161623.
22. Sharma, AC, Gulati, A: Role of nitric oxide in cardiovascular effects of diaspirin cross-linked (DCLHb) and stroma reduced hemoglobin (SRHb). FASEBJ 1994;8(5):A625. Abstract.
23. Xu, L, Sun, L, Rollwagen, FM, Li, Y, Pacheco, N, Pikoulis, E, Leppniemi, A, Soltero, R, Burris, D, Malcolm, D, Nielsen, TB: Cellular response to surgical trauma, hemorrhage, and resuscitation with diaspirin crosslinked hemoglobin in rats. J Trauma 1997;42(1):32–1.
24. Birnbaum, ML, Lipman, J, Garrioch, M, Daily, E, Przybelski, R: Diaspirin cross-linked hemoglobin (DCLHb) vs. blood in acutely anemic patients. Intensive Care Med 1997;23 (Supplement 1):S85. Abstract.
25. Malcolm, DS, Hamilton, IN, Schultz, SC, Cole, F, Burhop, K: Characterization of the hemodynamic response to intravenous diaspirin crosslinked hemoglobin solution in rats. Art Cells Blood Subs and Immob Biotech 1994;22(1):91107.
26. Sharma, AC, Gulati, A: Effect of diaspirin cross-linked hemoglobin and norepinephrine on systemic hemodynamics and regional circulation in rats. J Lab Clin Med 1994;123(2):299308.
27. Gulati, A, Singh, G, Rebello, S, Sharma, AC: Effect of diaspirin crosslinked and stroma-reduced hemoglobin on mean arterial pressure and endothelin-1 concentration in rats. Life Sciences 1995;56(17):14331442.
28. Gulati, A, Rebello, S: Diaspirin crosslinked hemoglobin (DCLHbTM): Involvement of adrenergic mechanisms in the pressor effect. Artif Cells Blood Subs and Immob Biotech 1994;22(3):603612.
29. Przybelski, RJ, Daily, EK, Kisicki, JC, Goldberg, CM, Bounds, MJ, Colburn, WA: Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med 1996;24(12):19932000.
30. Swan, SK, Halstenson, CE, Collins, AJ, Colburn, WA, Blue, J, Przybelski, RJ: Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Amer J Kid Dis 1995;26(6):918923.
31. Garrioch, M, Larbuisson, R, Brichant, JF, Lamy, M, Daily, E, Pryzbelski, R: The hemodynamic effects of diaspirin cross-linked hemoglobin (DCLHb) in the operative setting. Crit Care Med 1996;24(1):A39. Abstract
32. Rhea, G, Bodenham, AR, Mallick, A, Przybelski, R, Daily, EK: Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. Crit Care Med 1997;25(9):14801488.
33. Azari, M, Rohn, K, Picken, J: Diaspirin cross-linked hemoglobin (DCLHbTM): Characterization of the process and the product manufactured under GMP requirements for clinical studies. Art Cells Blood Subs and Immob Biotech 1994;22(3):701708.
34. Estep, TM, Bechtel, MK, Miller, TJ, Bagdasarian, A: Virus inactivation in hemoglobin solutions by heat. Biomat Art Cells Art Org 1988;16:129134.
35. Ryan, S, Sandler, A, Trenhaile, S, Ephgrave, K, Garner, S: Pancreatic enzyme elevations after blunt trauma. Surgery 1994;116:622627.
36. Boulanger, BR, Milzman, DP, Rosaati, C, Rodriguez, A: The clinical significance of acute hyperamylasemia after blunt trauma. Can J Surg 1993;36:6369.
37. Bouwman, DL, Weaver, DW, Walt, AJ: Serum amylase and its isoenzymes: A clarification of their implications in trauma. J Trauma; 1984:573578.
38. Takahashi, M, Maemura, K, Sawada, Y, Yoshioka, T, Sugimoto, T: Hyperamylasemia in critically injured patients. J Trauma 1980;20:951955.
39. Jurkovich, GJ and Carrico, CJ: Pancreatic trauma. Surg Clin North Am 1990;70:575593.



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed